Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Identifying children’s mental health issues with mHealth technology

Identifying children’s mental health issues with mHealth technology

The World Innovation Summit for Health (WISH) released a Report on Mental Health and Well-being for children titled “Healthy Young Minds. Transforming the mental health of children.” The information included on this blog post is taken from the report. 

The report revealed that half of all mental health problems emerge before individuals reach 18 years old. However, even in developed countries, only 25% receive any specialised treatment. Mental health problems place massive costs on society, since the total cost of mental illness is 3.5 of GDP in Europe.  Besides causing direct health care costs, mental illness in youths also causes educational failure, adolescent crime, teenage pregnancy.

Early intervention is fundamental. Parents, doctors and teachers need to become more open and informed, since mental illness is a common part of life. Schools need to prioritise children’s well-being and “life skills” should be added to the teaching curricula alongside mathematics and literature.

It is estimated that 31% of the world’s population is aged under 18, and 10% of them (which is equivalent to 220 million children) suffer from mental illness as it is illustrated in Figure 1. 

The costs of mental illness in children are quite considerable. Children with conduct disorder are four times more likely to commit a crime, take drugs, become teenage parents, depend on welfare, and attempt suicide, as it is illustrated in Table 1.

Figure-11

The costs of mental illness in children are quite considerable. Children with conduct disorder are four times more likely to commit a crime, take drugs, become teenage parents, depend on welfare, and attempt suicide, as it is illustrated in Table 1.

Table-11

The report estimated that in the UK alone, these children may cost in criminal justice, an amount equal to three years’ average wages.

These figures are severe enough by themselves. However, on top of that, at least 50% of the children who experience mental illness during their early years, will suffer from mental illness as an adult. [7] Their lives are more likely to be impoverished and unhappy, and they are much more likely to commit suicide.

The report mentions that these statistics shouldn’t be so high. Nowadays, there are multiple and effective treatments available for children suffering from mental illness. Besides, there is also an enormous opportunity in schools and communities to make significant changes that can reduce the likelihood of the problem in the first place.

Additionally, technology, and mobile health solutions are a huge advantage! Smartphone applications can contribute to monitor and train youths about mental health.

The WISH report encourages local communities and countries to focus on 10 Action Plans to improve the mental health of children around the world.

  • Community action: Every local community should implement a child well-being strategy. This plan should include an assessment of the needs of children and families; and the role of healthcare organisations, schools, and non-government organisations.
  • Parity of esteem: Mental health care for children and their parents should be widely available.
  • Universality: Health professionals should be trained to identify mental health problems in children, perinatal depression in mothers, and they should also be trained to treat these issues.
  • Professionals: Countries should train more professionals in evidence-based treatments, especially psychological therapy.
  • Well-being in Schools: The well-being of students should be the priority of every school, including the implementation of a Well-being Code of Conduct to which all teachers, parents, and students must adhere to.
  • Measurement: Schools should evaluate all student’s well-being on a continuous basis.
  • Add life-skills to the teaching curriculum: Schools should use evidence-based methods to provide explicit instruction in life throughout school life, especially in the early years.
  • Teacher Training: All teachers should be trained to notice and promote well-being and mental health.
  • Use of smartphone technology: Implement a smartphone-based program to promote mental health and well-being of the children.
  • The Sustainable development goals: The sustainable development goals should include physical and mental health.


The Monsenso mHealth solution can help facilitate the achievement six of the ten points included in the WISH Action Plan.

  • Use of smartphone technology and well-being at schools – The Monsenso smartphone app can help adolescents express any negative feelings they may be experiencing. This information can help care givers identify problems such as depression, anxiety, eating disorders, ADHD or even more severe diagnosis such as bipolar disorder or borderline.
  • Measurement – With help from the Monsenso mHealth platform, school personnel can identify if some students present any Triggers or Early Warning signs. Once symptoms are identified in a group of students, care givers can monitor this group closely to ensure they are receiving the support and attention they need.
  • Teacher training – The Monsenso web portal is so easy to use that care givers do not require any special training to use the system. However, since they are not trained as mental healthcare specialists, they will need some training to help them interpret the information provided through the self-assessments.
  • Parity of esteem – In most countries, there is a lack of resources and the waiting time to schedule an appointment with a mental healthcare specialist can be up to a year. The Monsenso mHealth solution can help school personnel identify the students who are experiencing symptoms of mental illness. Once a student has been monitored for a determined period and the symptoms continue, school personnel can recommend the family to seek professional help.
  • Add life-skills to the teaching curriculum – Since all students would be required to fill out the daily self-assessments to evaluate and monitor their mental health well-being, the class dialogue can be facilitated by the information on the system. Teachers can provide students with real, anonymous examples of a person experiencing symptoms. Additionally, students could be encouraged to talk to a school counsellor if they experience any of the symptoms discussed in class. Students could also be taught how to act if they notice any symptoms on their peers.

If you are interested in running a pilot with the Monsenso mHealth solution at your school, please contact us.

Reference:

Healthy Young Minds. Transforming the mental health of children. Report of the WISH Mental Health and Well-being in Children Forum 2015